Combination Therapy for OXA-48 Carbapenemase-Producing Klebsiella Pneumoniae Bloodstream Infections in Premature Infant: A Case Report and Literature Review

References

• Podschun R, Ullmann U. Klebsiella spp. as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity factors. Clin Microbiol Rev. 1998;11(4):589–603. doi:10.1128/CMR.11.4.589
   PubMed Web of Science ®Google Scholar
• Sands K, Carvalho MJ, Portal E, et al. Characterization of antimicrobial-resistant Gram-negative bacteria that cause neonatal sepsis in seven low- and middle-income countries. Nat Microbiol. 2021;6(4):512–523. doi:10.1038/s41564-021-00870-7
   PubMed Web of Science ®Google Scholar
• Han YL, Wen XH, Zhao W, et al. Epidemiological characteristics and molecular evolution mechanisms of carbapenem-resistant hypervirulent Klebsiella pneumoniae. Front Microbiol. 2022;13:1003783. doi:10.3389/fmicb.2022.1003783
   PubMed Web of Science ®Google Scholar
• Pu D, Zhao J, Chang K, Zhuo X, Cao B. ”Superbugs” with hypervirulence and carbapenem resistance in Klebsiella pneumoniae: the rise of such emerging nosocomial pathogens in China. Sci Bull. 2023;68(21):2658–2670. doi:10.1016/j.scib.2023.09.040
   PubMed Web of Science ®Google Scholar
• Lin XC, Li CL, Zhang SY, Yang XF, Jiang M. The global and regional prevalence of hospital-acquired carbapenem-resistant Klebsiella pneumoniae infection: a systematic review and meta-analysis. Open Forum Infect Dis. 2024;11(2):ofad649. doi:10.1093/ofid/ofad649
   PubMed Web of Science ®Google Scholar
• Hu F, Pan Y, Li H, et al. Carbapenem-resistant Klebsiella pneumoniae capsular types, antibiotic resistance and virulence factors in China: a longitudinal, multi-centre study. Nat Microbiol. 2024;9(3):814–829. doi:10.1038/s41564-024-01612-1
   PubMedGoogle Scholar
• Hu Y, Yang Y, Feng Y, et al. Prevalence and clonal diversity of carbapenem-resistant Klebsiella pneumoniae causing neonatal infections: a systematic review of 128 articles across 30 countries. PLoS Med. 2023;20(6):e1004233. doi:10.1371/journal.pmed.1004233
   PubMed Web of Science ®Google Scholar
• Shane AL, Sánchez PJ, Stoll BJ. Neonatal sepsis. Lancet. 2017;390(10104):1770–1780. doi:10.1016/S0140-6736(17)31002-4
   PubMed Web of Science ®Google Scholar
• Russell NJ, Stöhr W, Plakkal N, et al. Patterns of antibiotic use, pathogens, and prediction of mortality in hospitalized neonates and young infants with sepsis: a global neonatal sepsis observational cohort study (NeoOBS). PLoS Med. 2023;20(6):e1004179. doi:10.1371/journal.pmed.1004179
   PubMed Web of Science ®Google Scholar
• Fu P, Xu H, Jing C, et al. Bacterial epidemiology and antimicrobial resistance profiles in children reported by the ISPED program in China, 2016 to 2020. Microbiol Spectr. 2021;9(3):e0028321. doi:10.1128/Spectrum.00283-21
   PubMed Web of Science ®Google Scholar
• Chiotos K, Hayes M, Gerber JS, Tamma PD. Treatment of carbapenem-resistant Enterobacteriaceae infections in children. J Pediatric Infect Dis Soc. 2020;9(1):56–66. doi:10.1093/jpids/piz085
   PubMed Web of Science ®Google Scholar
• Karampatakis T, Tsergouli K, Behzadi P. Carbapenem-resistant Klebsiella pneumoniae: virulence factors, molecular epidemiology and latest updates in treatment options. Antibiotics. 2023;12(2):234. doi:10.3390/antibiotics12020234
   Google Scholar
• Katip W, Rayanakorn A, Oberdorfer P, Taruangsri P, Nampuan T, Okonogi S. Comparative effectiveness and mortality of colistin monotherapy versus colistin-fosfomycin combination therapy for the treatment of carbapenem-resistant Enterobacteriaceae (CRE) infections: a propensity score analysis. J Infect Public Health. 2024;17(5):727–734. doi:10.1016/j.jiph.2024.03.010
   PubMed Web of Science ®Google Scholar
• Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America 2023 guidance on the treatment of antimicrobial resistant gram-negative infections. Clin Infect Dis. 2023;1:3.
   Google Scholar
• Yin D, Wu S, Yang Y, et al. Results from the China Antimicrobial Surveillance Network (CHINET) in 2017 of the in vitro activities of ceftazidime-avibactam and ceftolozane-tazobactam against clinical isolates of Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2019;63(4). doi:10.1128/AAC.02431-18
   Web of Science ®Google Scholar
• de Jonge BL, Karlowsky JA, Kazmierczak KM, Biedenbach DJ, Sahm DF, Nichols WW. In vitro susceptibility to ceftazidime-avibactam of carbapenem-nonsusceptible Enterobacteriaceae isolates collected during the INFORM global surveillance study (2012 to 2014). Antimicrob Agents Chemother. 2016;60(5):3163–3169. doi:10.1128/AAC.03042-15
   PubMed Web of Science ®Google Scholar
• Marino A, Pulvirenti S, Campanella E, et al. Ceftazidime-Avibactam treatment for Klebsiella pneumoniae bacteremia in preterm infants in NICU: a clinical experience. Antibiotics. 2023;12(7):1169. doi:10.3390/antibiotics12071169
   Google Scholar
• Shirley M. Ceftazidime-avibactam: a review in the treatment of serious gram-negative bacterial infections. Drugs. 2018;78(6):675–692. doi:10.1007/s40265-018-0902-x
   PubMed Web of Science ®Google Scholar
• Pu W, Fan L, Zhang Y, You D, Li M, Ma L. Carbapenem-resistant Klebsiella pneumoniae osteoarthritis in two preterm infants treated with ceftazidime-avibactam. Pediatr Infect Dis J. 2023;42(12):1124–1127. doi:10.1097/INF.0000000000004092
   PubMed Web of Science ®Google Scholar
• Nascimento ADS, Passaro MF, Silva PSS, et al. Off-label use of ceftazidime-avibactam in a premature infant with multidrug-resistant Klebsiella pneumoniae infection: a case report. J Pharm Pract. 2023;36(4):1020–1025. doi:10.1177/08971900221087131
   PubMed Web of Science ®Google Scholar
• Monari C, Spagnuolo F, Pisaturo M, et al. Bloodstream infection due to a VIM-metallo-β-lactamase-producing Klebsiella pneumoniae treated with cefiderocol in a preterm newborn. Infect Dis Ther. 2023;12(2):727–734. doi:10.1007/s40121-022-00735-4
   PubMed Web of Science ®Google Scholar
• Bawankule S, Nabar N, Joshi P, Singhal T. Cefiderocol as salvage therapy for carbapenem-resistant Klebsiella pneumoniae sepsis in an extremely preterm neonate. Indian J Pediatr. 2023;90(3):310. doi:10.1007/s12098-022-04468-7
   PubMed Web of Science ®Google Scholar
• Asfour SS, Alaklobi FA, Abdelrahim A, et al. Intravenous ceftazidime-avibactam in extremely premature neonates with carbapenem-resistant Enterobacteriaceae: two case reports. J Pediatr Pharmacol Ther. 2022;27(2):192–197. doi:10.5863/1551-6776-27.2.192
   PubMedGoogle Scholar
• Weng B, Zhang X, Hong W, Yan C, Gong X, Cai C. A case of sepsis due to carbapenem-resistant Klebsiella pneumoniae in an extremely low-birth weight infant treated with trimethoprim-sulfamethoxazole. Infect Drug Resist. 2021;14:2321–2325. doi:10.2147/IDR.S312183
   PubMed Web of Science ®Google Scholar
• Wu YE, Xu HY, Shi HY, van den Anker J, Chen XY, Zhao W. Carbapenem-Resistant Enterobacteriaceae bloodstream infection treated successfully with high-dose meropenem in a preterm neonate. Front Pharmacol. 2020;11:566060. doi:10.3389/fphar.2020.566060
   PubMed Web of Science ®Google Scholar
• Coskun Y, Atici S. Successful treatment of pandrug-resistant Klebsiella pneumoniae infection with ceftazidime-avibactam in a preterm infant: a case report. Pediatr Infect Dis J. 2020;39(9):854–856. doi:10.1097/INF.0000000000002807
   PubMed Web of Science ®Google Scholar
• Iosifidis E, Chorafa E, Agakidou E, et al. Use of ceftazidime-avibactam for the treatment of extensively drug-resistant or pan drug-resistant Klebsiella pneumoniae in neonates and children <5 years of age. Pediatr Infect Dis J. 2019;38(8):812–815. doi:10.1097/INF.0000000000002344
   PubMed Web of Science ®Google Scholar
• Ciccia M, Ambretti S, Guerra L, Sandri F. Verona integron-encoded metallo-β-lactamase-producing Klebsiella pneumoniae sepsis in an extremely premature infant. Case Rep Perin Med. 2018;7(2). doi:10.1515/crpm-2018-0011
   Google Scholar
• Bonfanti P, Bellù R, Principe L, et al. Mother-to-child transmission of KPC carbapenemase-producing Klebsiella pneumoniae at birth. Pediatr Infect Dis J. 2017;36(2):228–229. doi:10.1097/INF.0000000000001403
   PubMed Web of Science ®Google Scholar
• Escobar Pérez JA, Olarte Escobar NM, Castro-Cardozo B, et al. Outbreak of NDM-1-producing Klebsiella pneumoniae in a neonatal unit in Colombia. Antimicrob Agents Chemother. 2013;57(4):1957–1960. doi:10.1128/AAC.01447-12
   PubMed Web of Science ®Google Scholar
• Dubey D, Sarangi R, Debata NK, Padhy RN. Detection of metallo β-lactamase producing Klebsiella pneumoniae in a neonatal septicemia. J Acute Dis. 2013;2(1):82–84. doi:10.1016/S2221-6189(13)60104-3
   Google Scholar
• Leiyan H, Pan F, Xia W, et al. Antimicrobial resistance profile of clinical strains isolated from children in China: a report from the ISPED program of 2020 (in Chinese). Chin J Evid Based Pediatr. 2021;16(06):414–420.
   Google Scholar
• Pan F, Chuanqing W, Hui Y, et al. Antimicrobial resistance profile of clinical strains isolated from children in China: a report from the ISPED program in 2021 (in Chinese). Chin J Evid Based Pediatr. 2022;17(05):355–362.
   Google Scholar
• Pan F, Chuanqing W, Hui Y, et al. Antimicrobial resistance profile of clinical strains isolated from children in China: report from the ISPED program in 2022 (in Chinese). Chin J Evid Based Pediatr. 2023;18(05):341–348.
   Google Scholar
• Fu P, Luo X, Shen J, et al. The molecular and epidemiological characteristics of carbapenemase-producing Enterobacteriaceae isolated from children in Shanghai, China, 2016–2021. J Microbiol Immunol Infect. 2023;56(1):48–56. doi:10.1016/j.jmii.2022.07.012
   PubMedGoogle Scholar
• Poirel L, Potron A, Nordmann P. OXA-48-like carbapenemases: the phantom menace. J Antimicrob Chemother. 2012;67(7):1597–1606. doi:10.1093/jac/dks121
   PubMed Web of Science ®Google Scholar
• Aracil-Gisbert S, Fernández-De-Bobadilla MD, Guerra-Pinto N, et al. The ICU environment contributes to the endemicity of the “Serratia marcescens complex” in the hospital setting. mBio. 2024;15(5):e0305423. doi:10.1128/mbio.03054-23
   PubMedGoogle Scholar
• Bonomo RA, Burd EM, Conly J, et al. Carbapenemase-Producing Organisms: a Global Scourge. Clin Infect Dis. 2018;66(8):1290–1297. doi:10.1093/cid/cix893
   PubMed Web of Science ®Google Scholar
• Potron A, Poirel L, Nordmann P. Derepressed transfer properties leading to the efficient spread of the plasmid encoding carbapenemase OXA-48. Antimicrob Agents Chemother. 2014;58(1):467–471. doi:10.1128/AAC.01344-13
   PubMed Web of Science ®Google Scholar
• Aghamohammad S, Khazani Asforooshani M, Malek Mohammadi Y, Sholeh M, Badmasti F. Decoding the genetic structure of conjugative plasmids in international clones of Klebsiella pneumoniae: a deep dive into blaKPC, blaNDM, blaOXA-48, and blaGES genes. PLoS One. 2023;18(11):e0292288. doi:10.1371/journal.pone.0292288
   PubMed Web of Science ®Google Scholar
• Stewart A, Harris P, Henderson A, Paterson D. Treatment of Infections by OXA-48-Producing Enterobacteriaceae. Antimicrob Agents Chemother. 2018;62(11). doi:10.1128/AAC.01195-18
   PubMed Web of Science ®Google Scholar
• Lin LY, Debabov D, Chang W, Stone G, Riccobene T. Antimicrobial activity of ceftazidime-avibactam and comparators against pathogens harboring OXA-48 and AmpC Alone or in Combination with Other β-Lactamases Collected from Phase 3 Clinical Trials and an International Surveillance Program. Antimicrob Agents Chemother. 2022;66(3):e0198521. doi:10.1128/aac.01985-21
   PubMed Web of Science ®Google Scholar
• Gutiérrez-Gutiérrez B, Salamanca E, de Cueto M, et al. Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. Lancet Infect Dis. 2017;17(7):726–734. doi:10.1016/S1473-3099(17)30228-1
   PubMed Web of Science ®Google Scholar
• Gutiérrez-Gutiérrez B, Salamanca E, de Cueto M, et al. A predictive model of mortality in patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae. Mayo Clin Proc. 2016;91(10):1362–1371. doi:10.1016/j.mayocp.2016.06.024
   PubMed Web of Science ®Google Scholar